LU86059A1 - Nouveaux analogues 6-substitues de la mitomycine - Google Patents
Nouveaux analogues 6-substitues de la mitomycine Download PDFInfo
- Publication number
- LU86059A1 LU86059A1 LU86059A LU86059A LU86059A1 LU 86059 A1 LU86059 A1 LU 86059A1 LU 86059 A LU86059 A LU 86059A LU 86059 A LU86059 A LU 86059A LU 86059 A1 LU86059 A1 LU 86059A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- methyl
- hydroxy
- methoxy
- hexahydro
- dione
- Prior art date
Links
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical class C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 title description 10
- -1 alkyl radical Chemical class 0.000 claims description 119
- 150000001875 compounds Chemical class 0.000 claims description 60
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 56
- 150000003254 radicals Chemical group 0.000 claims description 47
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- QMRIWYCCTCNABA-UHFFFAOYSA-N indole-4,7-quinone Chemical compound O=C1C=CC(=O)C2=C1C=CN2 QMRIWYCCTCNABA-UHFFFAOYSA-N 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000004001 thioalkyl group Chemical group 0.000 claims description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000005336 allyloxy group Chemical group 0.000 claims description 2
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000466 oxiranyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 46
- 239000000243 solution Substances 0.000 description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 230000008034 disappearance Effects 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- HYFMSAFINFJTFH-NGSRAFSJSA-N mitomycin A Chemical class O=C1C(OC)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@]1(OC)N2C[C@@H]2N[C@@H]21 HYFMSAFINFJTFH-NGSRAFSJSA-N 0.000 description 18
- HYFMSAFINFJTFH-UHFFFAOYSA-N Mitomycin-A Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)N2CC2NC21 HYFMSAFINFJTFH-UHFFFAOYSA-N 0.000 description 17
- 238000000354 decomposition reaction Methods 0.000 description 17
- 238000002844 melting Methods 0.000 description 17
- 230000008018 melting Effects 0.000 description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 15
- 235000011089 carbon dioxide Nutrition 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 8
- 238000012746 preparative thin layer chromatography Methods 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 description 5
- 229960004857 mitomycin Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229930192392 Mitomycin Natural products 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- WPOPOPFNZYPKAV-UHFFFAOYSA-N cyclobutylmethanol Chemical compound OCC1CCC1 WPOPOPFNZYPKAV-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- LAMUXTNQCICZQX-UHFFFAOYSA-N 3-chloropropan-1-ol Chemical compound OCCCCl LAMUXTNQCICZQX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- CIZVQWNPBGYCGK-UHFFFAOYSA-N benzenediazonium Chemical compound N#[N+]C1=CC=CC=C1 CIZVQWNPBGYCGK-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960002887 deanol Drugs 0.000 description 2
- 239000012972 dimethylethanolamine Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- NYPGBHKJFKQTIY-TYYBGVCCSA-N 2-cyanoethylazanium;(e)-4-hydroxy-4-oxobut-2-enoate Chemical compound NCCC#N.OC(=O)\C=C\C(O)=O NYPGBHKJFKQTIY-TYYBGVCCSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- UZUUQCBCWDBYCG-DQRAMIIBSA-N mitomycin B Chemical class O=C1C(OC)=C(C)C(=O)C2=C1[C@H](COC(N)=O)[C@]1(O)N2C[C@H]2[C@@H]1N2C UZUUQCBCWDBYCG-DQRAMIIBSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 125000003186 propargylic group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64705584 | 1984-09-04 | ||
| US06/647,055 US4888341A (en) | 1984-09-04 | 1984-09-04 | 6-substituted mitomycin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU86059A1 true LU86059A1 (fr) | 1986-02-18 |
Family
ID=24595518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU86059A LU86059A1 (fr) | 1984-09-04 | 1985-08-29 | Nouveaux analogues 6-substitues de la mitomycine |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4888341A (es) |
| JP (1) | JPS6168489A (es) |
| KR (1) | KR900006855B1 (es) |
| AT (1) | AT391318B (es) |
| AU (1) | AU593773B2 (es) |
| BE (1) | BE903168A (es) |
| CA (1) | CA1249278A (es) |
| CH (1) | CH666036A5 (es) |
| DE (1) | DE3531197A1 (es) |
| DK (1) | DK399985A (es) |
| ES (2) | ES8800225A1 (es) |
| FI (1) | FI81581C (es) |
| FR (1) | FR2569697B1 (es) |
| GB (1) | GB2164036B (es) |
| GR (1) | GR852066B (es) |
| HU (1) | HU194884B (es) |
| IT (1) | IT1203633B (es) |
| LU (1) | LU86059A1 (es) |
| NL (1) | NL8502203A (es) |
| NO (1) | NO162618C (es) |
| PT (1) | PT81084B (es) |
| SE (1) | SE468212B (es) |
| ZA (1) | ZA854452B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927943A (en) * | 1984-09-04 | 1990-05-22 | Bristol-Myers Company | Substituted 7-oxomitosanes |
| AU581673B2 (en) * | 1984-09-04 | 1989-03-02 | Bristol-Myers Company | Substituted 7-oxomitosanes |
| US5097036A (en) * | 1984-09-04 | 1992-03-17 | Bristol-Myers Company | Substituted 7-oxomitosanes |
| CA1282069C (en) * | 1985-09-12 | 1991-03-26 | Damon L. Meyer | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
| DE3871836T2 (de) * | 1987-03-25 | 1993-01-14 | Kyowa Hakko Kogyo Kk | Mitomycin-derivate. |
| US5023253A (en) * | 1987-12-21 | 1991-06-11 | University Patents, Inc. | 6-substituted mitomycin analogs |
| US5099016A (en) * | 1988-11-07 | 1992-03-24 | Bristol-Myers Company | Substituted 7-oxomitosanes |
| DE69127345D1 (de) * | 1990-11-13 | 1997-09-25 | Kyowa Hakko Kogyo Kk | Mitomycinderivate |
| DE10212359B4 (de) * | 2002-03-20 | 2005-10-06 | Peter Lisec | Verfahren und Vorrichtung zum maschinellen Applizieren eines Abstandhalterbandes auf eine Glasscheibe |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA770128A (en) * | 1967-10-24 | Matsui Masanao | 7-HYDROXY-9.alpha.-METHOXY MITOSANE AND PROCESS FOR PREPARING THE SAME | |
| CA770608A (en) * | 1967-10-31 | Matsui Masanao | 1a-substituted mitomycin | |
| US3306821A (en) * | 1962-09-04 | 1967-02-28 | Upjohn Co | Porfiromycin derivatives and method of making same |
| NL132363C (es) * | 1964-07-10 | |||
| DE1570030A1 (de) * | 1964-07-11 | 1970-04-09 | Kyowa Hakko Kogyo Kk | Verfahren zur Herstellung von in 1a-Stellung substituierten Mitomycinverbindungen |
| JPS5748985A (en) * | 1980-09-09 | 1982-03-20 | Kyowa Hakko Kogyo Co Ltd | Novel mitomycin derivative |
| US4746746A (en) * | 1983-02-07 | 1988-05-24 | University Patents, Inc. | Mitomycin analogs |
| US4803212A (en) * | 1983-04-11 | 1989-02-07 | Bristol-Myers Company | Amino disulfides |
| US4814445A (en) * | 1984-09-04 | 1989-03-21 | Bristol-Myers Company | Process for preparing mitomycin analogs |
| AU581673B2 (en) * | 1984-09-04 | 1989-03-02 | Bristol-Myers Company | Substituted 7-oxomitosanes |
-
1984
- 1984-09-04 US US06/647,055 patent/US4888341A/en not_active Expired - Fee Related
-
1985
- 1985-06-13 ZA ZA854452A patent/ZA854452B/xx unknown
- 1985-07-05 KR KR1019850004843A patent/KR900006855B1/ko not_active IP Right Cessation
- 1985-07-18 GB GB08518099A patent/GB2164036B/en not_active Expired
- 1985-07-23 AT AT0218185A patent/AT391318B/de not_active IP Right Cessation
- 1985-07-24 CA CA000487369A patent/CA1249278A/en not_active Expired
- 1985-08-07 NL NL8502203A patent/NL8502203A/nl not_active Application Discontinuation
- 1985-08-07 AU AU45882/85A patent/AU593773B2/en not_active Ceased
- 1985-08-09 IT IT67722/85A patent/IT1203633B/it active
- 1985-08-19 FI FI853181A patent/FI81581C/fi not_active IP Right Cessation
- 1985-08-27 GR GR852066A patent/GR852066B/el unknown
- 1985-08-29 LU LU86059A patent/LU86059A1/fr unknown
- 1985-08-31 DE DE19853531197 patent/DE3531197A1/de not_active Withdrawn
- 1985-09-02 DK DK399985A patent/DK399985A/da not_active Application Discontinuation
- 1985-09-02 FR FR858513003A patent/FR2569697B1/fr not_active Expired - Fee Related
- 1985-09-03 PT PT81084A patent/PT81084B/pt not_active IP Right Cessation
- 1985-09-03 HU HU853336A patent/HU194884B/hu not_active IP Right Cessation
- 1985-09-03 ES ES546690A patent/ES8800225A1/es not_active Expired
- 1985-09-03 NO NO853468A patent/NO162618C/no unknown
- 1985-09-03 CH CH3790/85A patent/CH666036A5/de not_active IP Right Cessation
- 1985-09-03 BE BE0/215534A patent/BE903168A/fr not_active IP Right Cessation
- 1985-09-03 JP JP60195692A patent/JPS6168489A/ja active Pending
- 1985-09-04 SE SE8504113A patent/SE468212B/sv not_active IP Right Cessation
-
1987
- 1987-05-28 ES ES557566A patent/ES8800227A1/es not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH05508619A (ja) | ヒト結腸直腸癌の有効な抑制剤であるカンプトセシンアナローグ | |
| FR2501207A1 (fr) | Composes quinazoliniques antitumoraux et leur procede de production | |
| WO1992019620A1 (fr) | Nouveaux derives de pyrrolo [1, 4]-benzodiazepines, leur procede de preparation et medicaments les contenant | |
| FR2565232A1 (fr) | Nouveaux diesters d'acides gras et d'a,a-trehalose, leur procede de preparation et leur application en therapeutique | |
| FR2477016A1 (fr) | Compositions pharmaceutiques a base de derives de mitomycine pour le traitement de maladie neoplastique chez les animaux | |
| LU86059A1 (fr) | Nouveaux analogues 6-substitues de la mitomycine | |
| EP0576619B1 (fr) | Compositions therapeutiques a base de derives de 1,2-dithiole-3-thione | |
| FR2580642A1 (fr) | 5-pyrimidinecarboxamides et traitement de la leucemie et des tumeurs en les utilisant | |
| JPH02502543A (ja) | 新規６置換マイトマイシン類似体 | |
| FR2499577A1 (fr) | Nouvelles 1-(2-chloroethyl)-1-nitrosourees-3-substituees par un reste de sucre, utiles notamment comme agents antitumoraux et leur procede de preparation | |
| LU84144A1 (fr) | Analogues de la mitomycine | |
| BE1003519A3 (fr) | Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
| EP0739887A1 (fr) | Nouveaux composés cyclohexaniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| CA2463923A1 (fr) | Nouveaux derives d'hydroxyalkyle indolocarbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| EP0215687B1 (fr) | Substance biologiquement active, appelée girolline, extraité de l'éponge Pseudaxinyssa cantharella, son procédé de préparation et les compositions pharmaceutiques qui la contiennent | |
| EP0699679A1 (fr) | Nouveaux composés tétrahydropyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| SU1251806A3 (ru) | Способ получени 7-замещенных 9а-метоксимитозана | |
| JPS63264580A (ja) | ３−（２−ハロアルキル）−１，４−オキサチインおよび２−（２−ハロアルキル）−１，４−ジチイン | |
| FR2529891A1 (fr) | Derives du pyridyl-3 alcoxy-5 pyrazole, procede de preparation et application en therapeutique | |
| FR2510577A1 (fr) | Composes organiques azotes extraits de plantes et leurs derives, leur preparation et leurs utilisations therapeutiques, notamment en tant qu'agents antineoplastiques | |
| BE867095A (fr) | Nouveaux derives sesquiterpeniques utiles notamment comme inhibiteurs du systeme complementaire et leurs procedes de preparation | |
| FR2485015A1 (fr) | Derives de l'olivacine et leur application therapeutique | |
| BE887456R (fr) | Procede de production de composes intermediaires pour l'obtention de la spectinomycine et de ses analogues et produits de ce procede | |
| KR0169357B1 (ko) | 신규한 2-이미다졸론유도체 및 그의 제조방법 | |
| FR2534259A1 (fr) | Diester d'acide aliphatique a chaine moyenne en positions 6, 6' d'a,a-trehalose et son application en therapeutique |